Citizens cut Nasus Pharma's price target to $18 on Mar 26, 2026 (Investing.com); the valuation-led revision signals a sector re-rating and warrants model-by-model review.

Nasus Pharma Ltd. (NYSE American: NSRX) priced its initial public offering of 1,250,000 ordinary shares at $8.00 per share, generating gross proceeds of $10 million before deducting underwriting fees and expenses, according to a company statement. The Tel Aviv-based clinical-stage pharmaceutical company granted underwriters a 45-day option to purchase up to an additional 187,500 shares at the offering price to cover over-allotments. Laidlaw & Company (UK) Ltd. and Craft Capital Management LLC served as joint bookrunners for the offering. The company’s shares received approval for listing on the NYSE American and began trading on August 13, 2025, under the ticker symbol "NSRX." The offering closed on August 14, 2025. Nasus Pharma stated it plans to use net proceeds to advance development of its intranasal epinephrine program, including manufacturing scale-up and additional Phase 2 studies. Remaining funds will support general administrative purposes, working capital, and capital expenditures. The Securities and Exchange Commission declared the company’s registration statement on Form F-1 (File No. 333-288582) effective on August 12, 2025. Nasus Pharma develops intranasal powder products for acute medical conditions. Its lead product candidate, NS002, is an intranasal powder epinephrine treatment designed as an alternative to epinephrine autoinjectors for patients with anaphylaxis. The company’s proprietary powder-based intranasal technology uses the nasal cavity’s vascular network for drug absorption. With valuations skyrocketing in 2024, many investors are uneasy putting more money into stocks. Unsure where to invest next? Get access to our proven portfolios and discover high-potential opportunities. In 2024 alone, ProPicks AI identified 2 stocks that surged over 150%, 4 additional stocks that leaped over 30%, and 3 more that climbed over 25%. That's an impressive track record. With portfolios tailored for Dow stocks, S&P stocks, Tech stocks, and Mid Cap stocks, you can explore various wealth-building strategies.

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.